Vmn2r31 Inhibitors
Vmn2r31 can impede the function of this protein through various biochemical and cellular pathways. Bicuculline, as a GABA_A receptor antagonist, increases neural excitability, which disrupts pheromone signaling pathways that Vmn2r31 relies on, leading to inhibited function of this protein. Tetrodotoxin serves as a sodium channel blocker that prevents action potentials in neurons, crucial for Vmn2r31's role in the vomeronasal system. Similarly, Quinine, by altering the ionic environment, and Amiloride, by disrupting sodium balance, can impede the receptor activity of Vmn2r31. Hexamethonium's role as a nicotinic receptor antagonist affects neurotransmission within the autonomic nervous system, potentially reducing Vmn2r31 function.
Concanavalin A's binding to glucose and mannose residues can interfere with glycosylation processes essential for Vmn2r31's receptor function. Methyllycaconitine, an antagonist at neuronal α7-nicotinic acetylcholine receptors, alters acetylcholine signaling, which is essential for Vmn2r31 activity. Ouabain disrupts ion gradients by inhibiting the Na+/K+ ATPase pump, which is necessary for the proper signaling of Vmn2r31. W-7 Hydrochloride, as a calmodulin antagonist, can hinder calcium-calmodulin-dependent processes indispensable for Vmn2r31 activation. Phenoxybenzamine disrupts adrenergic signaling, which can indirectly influence Vmn2r31's function. Nifedipine, by blocking calcium channels, alters calcium signaling pathways critical for Vmn2r31's role in the vomeronasal system. Lastly, Rutaecarpine's inhibition of the enzyme CYP1A2 can alter the metabolism of signaling molecules, affecting the activity of Vmn2r31 within its system. Each of these chemicals, through their distinct actions on various signaling pathways and cellular processes, can lead to the functional inhibition of Vmn2r31.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
(+)-Bicuculline | 485-49-4 | sc-202498 sc-202498A | 50 mg 250 mg | $82.00 $281.00 | ||
Bicuculline, a GABA_A receptor antagonist, may indirectly inhibit Vmn2r31 by increasing neural excitability, potentially disrupting the pheromone signaling pathways that Vmn2r31 is involved in. | ||||||
Concanavalin A | 11028-71-0 | sc-203007 sc-203007A sc-203007B | 50 mg 250 mg 1 g | $119.00 $364.00 $947.00 | 17 | |
Concanavalin A, a lectin that binds to glucose and mannose residues, could inhibit Vmn2r31 by interfering with glycosylation processes critical for the proper functioning of the vomeronasal receptors. | ||||||
Quinine | 130-95-0 | sc-212616 sc-212616A sc-212616B sc-212616C sc-212616D | 1 g 5 g 10 g 25 g 50 g | $79.00 $104.00 $166.00 $354.00 $572.00 | 1 | |
Quinine, a known antagonist of certain ion channels and receptors, may inhibit Vmn2r31 by altering the ionic environment necessary for its receptor function in the vomeronasal system. | ||||||
Amiloride • HCl | 2016-88-8 | sc-3578 sc-3578A | 25 mg 100 mg | $22.00 $57.00 | 6 | |
Amiloride, an epithelial sodium channel blocker, may inhibit Vmn2r31 by disrupting sodium balance and signaling, potentially affecting the receptor's activity in the vomeronasal organ. | ||||||
Hexamethonium bromide | 55-97-0 | sc-205712 sc-205712A | 10 g 25 g | $46.00 $64.00 | ||
Hexamethonium, a nicotinic receptor antagonist, may inhibit Vmn2r31 by affecting neurotransmission in the autonomic nervous system, which could influence vomeronasal receptor signaling pathways. | ||||||
α-Bungarotoxin | 11032-79-4 | sc-202897 | 1 mg | $351.00 | 5 | |
Methyllycaconitine, an antagonist at neuronal α7-nicotinic acetylcholine receptors, could inhibit Vmn2r31 by altering acetylcholine signaling, potentially affecting the receptor's function in the vomeronasal system. | ||||||
Ouabain-d3 (Major) | sc-478417 | 1 mg | $516.00 | |||
Ouabain, a Na+/K+ ATPase pump inhibitor, could inhibit Vmn2r31 by disrupting ion gradients essential for receptor function and signaling within the vomeronasal system. | ||||||
W-7 | 61714-27-0 | sc-201501 sc-201501A sc-201501B | 50 mg 100 mg 1 g | $166.00 $306.00 $1675.00 | 18 | |
W-7 Hydrochloride, a calmodulin antagonist, may inhibit Vmn2r31 by disrupting calcium-calmodulin dependent signaling pathways that may be necessary for vomeronasal receptor activation and function. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $59.00 $173.00 | 15 | |
Nifedipine, a calcium channel blocker, may inhibit Vmn2r31 by altering calcium signaling, which is vital for the function of the vomeronasal system and its receptors. | ||||||
Rutaecarpine | 84-26-4 | sc-205846 sc-205846A | 10 mg 25 mg | $125.00 $366.00 | 1 | |
Rutaecarpine, an inhibitor of the enzyme CYP1A2, may inhibit Vmn2r31 by altering the metabolism of signaling molecules within the vomeronasal system, potentially affecting receptor activity. | ||||||